arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Dermata Therapeutics, Inc.

DRMA

$1.10 ▼ -0.01 (-0.90%) at close

7 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Dermata Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -98.7% ↗

FCF / Share $-8.38 ↗

Trailing P/E —

Price / Book 0.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-7.56M

↑ +38.5% —

FCF / Share Free cash flow per share

$-8.38

↑ +88.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	89.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-100.9% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-4496.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	64.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-43.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	38.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-57.6% Weak ↓ Weak Declining Year-over-year change in net income	18.9% Good ↑ Good Improving Year-over-year change in net income	-21.6% Weak Weak Year-over-year change in net income	-144.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	88.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	37.2% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.24x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-98.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-633.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-100.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-126.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-61.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	78.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-98.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-354.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-100.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-139.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-524.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-121.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-910%)	—	-122.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-918%)	-159.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1164%)	-78.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-621%)	101.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+579%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	-172.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	-16.08x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-7.52M	$-3.16M	—	$-6.24M	$-10.80M	$-530.40K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-8.16	$-80.32	$-39.99	$-0.87	$-2.43	$-1.69	—
Free Cash Flow per Share (USD)	$-8.38	$-72.97	—	—	$-1.32	$-2.11	—
Book Value per Share (USD)	$2.34	$6.20	$24.26	$0.49	$1.21	$-1.66	—
Tangible Book Value per Share (USD)	$2.34	$6.20	$24.26	$0.49	$1.21	$-1.66	—
Basic Weighted Avg Shares (shares)	926,192	152,974	—	—	4.30M	1.91M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	—	—	—	—	$10.11M	$-3.18M	—
Total Equity (USD)	$6.22M	$1.56M	$6.36M	$6.02M	$10.11M	$-3.18M	$-210.16K

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Income, GAAP (USD)	$-7.56M	$-12.29M	$-7.79M	$-9.61M	$-7.90M	$-3.24M	—
Operating Cash Flow (USD)	$-7.76M	$-11.16M	$-6.41M	$-8.83M	$-5.69M	$-4.03M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Dermata Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DRMA with peers